로딩 중…
지수 로딩 중…
Chong Kun Dang Pharmaceutical Corp.
185750· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩64,400-1.08%
2026-09-18
Financials
Valuation Metrics
Chong Kun Dang Pharmaceutical Corp.'s Market Cap is ₩8889B. At end of 2025 it was ₩1.1T. Ranked #322 of 2,421 in KR market (top 13%), #237 of 781 on KOSPI (top 30%), #35 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 888.90B KRW | KR#322/2,421 Sec#35/231 |
| Revenue | 1.78T KRW | KR#278/2,421 Sec#7/231 |
| Net Income | 79.57B KRW | KR#295/2,421 Sec#21/231 |
| Total Assets | 1.87T KRW | KR#312/2,421 Sec#13/231 |
| Net Assets | 1.02T KRW | KR#293/2,421 Sec#17/231 |
| Employees | 2,336 | KR#125/2,421 Sec#5/231 |
| Value | ||
| P/E | 11.17x | KR#878/2,421 Sec#47/231 |
| P/B | 0.87x | KR#1,341/2,421 Sec#84/231 |
| PEG | 0.42x | KR#673/2,421 Sec#43/231 |
| P/S | 0.50x | KR#923/2,421 Sec#43/231 |
| EV/EBITDA | 14.58x | KR#837/2,421 Sec#50/231 |
| FCF Yield | -8.28% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 7.81% | KR#809/2,421 Sec#53/231 |
| ROA | 4.26% | KR#823/2,421 Sec#65/231 |
| Op. Margin | 4.33% | KR#1,052/2,421 Sec#76/231 |
| Revenue Growth | 7.15% | KR#1,066/2,421 Sec#102/231 |
| Earnings Growth | 26.88% | KR#665/2,421 Sec#45/231 |
| Financial Health | ||
| Debt Ratio | 83.26% | KR#1,392/2,421 Sec#161/231 |
| Total Debt | 428.32B KRW | KR#337/2,421 Sec#12/231 |
| FCF | -73.56B KRW | KR#2,108/2,421 Sec#207/231 |
| Cash | 192.29B KRW | KR#276/2,421 Sec#10/231 |
| Current Ratio | 2.04x | KR#851/2,421 Sec#97/231 |
| Net Debt/EBITDA | 3.06x | KR#910/2,421 Sec#67/231 |
| Dividend | ||
| Div. Yield | 0.78% | KR#1,177/2,421 Sec#72/231 |
| Div. Growth | -54.55% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -23.33% | KR#1,359/2,421 Sec#97/231 |
| 1M Return | -4.17% | KR#1,714/2,421 Sec#135/231 |
| From 52W High | -34.35% | KR#678/2,421 Sec#44/231 |
| 1Y MDD | -34.39% | KR#382/2,421 Sec#28/231 |
| Trading | ||
| Volume | 28,410 shares | KR#1,413/2,421 Sec#139/231 |
| Trading Value | 1.83B KRW | KR#576/2,421 Sec#56/231 |
| Foreign Own. | 15.62% | KR#304/2,421 Sec#18/231 |
| Per Share | ||
| EPS | 5,764 KRW | KR#189/2,421 Sec#9/231 |
| BPS | 73,777 KRW | KR#187/2,421 Sec#12/231 |
Company Info
동사는 1941년 궁본약방으로 설립되어 2013년 인적분할을 통해 의약품사업부문을 담당하는 신설회사로 재편되었으며, 유가증권시장에 재상장함. 국내 대형 제약사로서 신약 캄토벨과 듀비에정, 네스플 출시하였고 2023년 노바티스사와 HDAC6 저해제 CKD-510 기술수출 계약 체결함. 동사는 신약, 바이오의약품 연구개발과 해외시장 개척을 통해 글로벌 제약기업으로 도약하고 있음. 종근당는 2013년에 설립되었으며 서울 서대문구에 본사를 두고 있습니다.